PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 23, 2026Biochemistry and Biophysics Reports0 citationsOpen Access

Regulation of epidermal growth factor receptors: The role of c-Cbl, Cdc42, and miRNAs in breast cancer

View Full Paper
SASabina Ekua AndamETEmmanuel Ayitey TagoeAAAnastasia Rosebud Aikins

Key Points

  • This review aims to explore the regulation of EGFR and its implications in breast cancer pathology.
  • Review of existing literature on EGFR regulation in breast cancer
  • Analysis of roles of c-Cbl, Cdc42, and miRNAs
  • Discussion of molecular mechanisms involving signaling pathways
  • EGFR dysregulation is associated with breast cancer progression
  • c-Cbl is crucial for EGFR degradation via ubiquitination
  • Cdc42 is identified as a negative regulator of c-Cbl, enhancing EGFR signaling
  • MicroRNAs act as modulators influencing tumor evolution
  • Potential therapeutic targets involve EGFR–c-Cbl–Cdc42–miRNA interactions

Abstract

Breast cancer, a global health issue, is marked by increasing prevalence and diverse molecular subtypes, which complicate effective treatment strategies. A relevant aspect in breast cancer etiology and development is epidermal growth factor receptor (EGFR) dysregulation. This review examines the intricate regulation of EGFR, focusing on the roles of signaling molecules and microRNAs (miRNAs) in EGFR regulation in breast cancer. The paper delves into the molecular mechanisms underlying EGFR dimerization, activation, and downstream routes for signaling, emphasizing the roles of signaling molecules such as Cbl and Cdc42. Furthermore, the emerging role of miRNAs as essential modulators of gene activity in breast cancer is discussed, focusing on differential expression patterns and functional implications in tumor progression. By elucidating the regulatory networks involving EGFR, signaling molecules, and miRNAs, the current review offers insights into potential therapeutic targets and avenues for future research in breast cancer. • EGFR dysregulation is a key driver of breast cancer pathogenesis. • c-Cbl promotes EGFR degradation through ubiquitination. • Cdc42 impairs c-Cbl, sustaining EGFR signaling. • MicroRNAs modulate breast cancer progression as oncogenes or tumor suppressors. • Targeting EGFR–c-Cbl–Cdc42–miRNA networks presents new therapeutic avenues.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Andam et al. (2026) studied this question.

synapsesocial.com/papers/69c08bcaa48f6b84677f99fchttps://doi.org/10.1016/j.bbrep.2026.102556
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies2013 · 408 citations
  2. 2EGFR and cancer prognosis2001 · 2,162 citations
  3. 3Messenger RNA capture sequencing of extracellular RNA from human biofluids using a comprehensive set of spike-in controls2021 · 17 citations
  4. 4Perceived Breast Cancer Risk among Female Undergraduate Students in Ghana: A Cross-Sectional Study2021 · 18 citations
  5. 5Investigation of the regulation of EGF signaling by miRNAs, delving into the underlying mechanism and signaling pathways in cancer2024 · 5 citations